Labcorp launches new test for risk assessment and prognosis of severe preeclampsia in pregnant women

B•r•a•h•m•s™ sflt-1/plgf kryptor™ test system is available through physicians and is the first fda-cleared biomarker test to aid in the risk assessment of progression to preeclampsia with severe features, a leading cause of maternal and fetal mortality in the u.s.1 burlington, n.c. , jan. 31, 2024 /prnewswire/ -- labcorp (nyse: lh), a global leader of innovative and comprehensive laboratory services, today announced the launch and availability of a new, fda-cleared blood test for risk assessment and clinical management of severe preeclampsia, a life-threatening blood pressure disorder that occurs during pregnancy and the postpartum period.
LH Ratings Summary
LH Quant Ranking